Alaunos Therapeutics (NASDAQ:TCRT) Upgraded at Wells Fargo & Company

Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a research report issued on Wednesday, The Fly reports.

Several other brokerages have also recently commented on TCRT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alaunos Therapeutics in a research report on Friday, April 1st. HC Wainwright reiterated a “neutral” rating on shares of Alaunos Therapeutics in a research report on Thursday, March 31st. Finally, Raymond James set a $2.00 price target on shares of Alaunos Therapeutics and gave the stock a “market perform” rating in a research report on Friday, April 1st.

TCRT opened at $0.56 on Wednesday. The company has a quick ratio of 4.91, a current ratio of 4.91 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $119.85 million, a price-to-earnings ratio of -1.50 and a beta of 1.58. Alaunos Therapeutics has a 1-year low of $0.41 and a 1-year high of $3.73.

Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last issued its quarterly earnings results on Wednesday, March 30th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. As a group, equities research analysts forecast that Alaunos Therapeutics will post -0.32 EPS for the current year.

About Alaunos Therapeutics (Get Rating)

Alaunos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells.

See Also